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Background
Breast cancer is the most common cancer affecting women worldwide, in both developed 
and developing countries. Every year, there are approximately 1.38 million new cases of 
breast cancer and 458,000 deaths caused by it (International Agency for Research on 
Cancer 2010). Breast cancer was the most common female cancer in the United King-
dom and United States in 2010 (Jemal et al. 2010), with the lifetime risk of breast cancer 
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for women in the United Kingdom being 1 in 8 (Cancer Research UK 2013). In Taiwan, 
breast cancer is the fourth leading cancer (in both sexes combined), and the government 
recommends free mammogram screening for all women over 40 years of age once every 
2 years (Health Promotion Administration 2010; Ng 2011).
Studies, including large-scale randomized trials, have investigated potential preven-
tive agents against breast cancer. However, identifying an agent that will be accepted by 
patients for primary prevention is challenging (Higgins et  al. 2012). Statins are widely 
prescribed for managing chronic hypercholesterolemia and associated morbidities. After 
patients begin taking statins, they commonly use these agents for a long time (Ahern 
et al. 2011). If statins were proven to have a protective effect against breast cancer, then 
this added incentive may increase patient compliance. In high-risk populations, statins 
may be feasible agents to help prevent breast cancer. Thus, there is increasing interest 
in the potential effects of statins on breast cancer (Campbell et al. 2006), and proving 
a connection between statin use and breast cancer risk would have major public health 
implications.
In this study, the risk of breast cancer is statistically evaluated for statin users and non-
users in Taiwan, as well as for each statin.
Methods
Study population and study design
A retrospective case–control design was used. The cases and controls were retrieved 
from the Longitudinal Health Insurance Database 2005 (LHID2005), which is part of the 
Taiwanese NHI Database. The NHI program covers approximately 99% of the popula-
tion of Taiwan, with over 22 million enrollees. LHID2005 comprises a random sample of 
1 million of these, and includes data on ambulatory care, inpatient care, demographics, 
diagnostic codes, prescription details, and the expenses incurred by enrollees.
The study cases were women for whom a diagnosis of breast cancer (ICD-9-CM code 
174.X) had been recorded in LHID2005 between January 1, 2004 and December 31, 
2010. The ICD-9-CM codes had all been recorded by trained physicians on the basis 
of pathological evidence. To ensure the validity of the breast cancer diagnoses, only 
patients who received at least two consistent diagnoses of breast cancer were selected. 
The study did not include patients only diagnosed once because they may have been 
too sick or in the late stage of the disease, which was not our study focus. In addition, 
patients younger than 18 years were excluded from the study. As a result, 4332 breast 
cancer patients were included in the study.
Controls were selected from among the remaining women in the LHID2005. Women 
were excluded if they had been diagnosed with breast cancer. The 21,660 participants 
selected were matched with the cases in a ratio of five to one according to age at the 
time of diagnosis (18–30, 31–40, 41–50, 51–60, 61–70, and >70 years) and the year at 
cohort entry from the remaining patients without a diagnosis of breast cancer in the 
LHID 2005.
Medication exposure
Exposure to statins and other medications was identified using a drug prescription data-
base. Cases and controls were considered to have been exposed to statins if they received 
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them within the 3 years prior to the index date, which was the date of the breast cancer 
diagnosis for the cases or, for the controls, the date on which the matched case received 
a breast cancer diagnosis. The statins included simvastatin (ATC code C10AA01), lov-
astatin (ATC code C10AA02), pravastatin (ATC code C10AA03), fluvastatin (ATC code 
C10AA04), and atorvastatin (ATC code C10AA05).
The Charlson Comorbidity Index (CCI) score was assessed according to the 16 Charl-
son comorbidities (Quan et al. 2005) including myocardial infarction, congestive heart 
failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmo-
nary disease, connective tissue disease-rheumatic disease, peptic ulcer disease, mild liver 
disease, diabetes, paraplegia and hemiplegia, renal disease, moderate or severe liver dis-
ease, metastatic carcinoma, AIDS/HIV, using diagnoses (excluding cancer) recorded in 
the NHI before the index date. Other covariates of interest, including age and urbaniza-
tion level, were obtained for all the cases and controls.
Statistical analysis
The cluster random effect of urbanization often affects estimates of bias in clinical 
research. In this study, we took into consideration the bias caused by random urbaniza-
tion through the following proposed model: logit(P(Yij = 1|ui)) = α+ ui + βXij, where 
Yij = 1 denoted obtained breast cancer, and ui (for i = 1, 2, …, 5) denotes a vector of 
urbanization random effects, which are normally distributed. X denotes covariates of 
interest in the model. A logistic regression model coupled with a random urbanization 




 was used to compare our proposed model 
with the traditional logistic regression model. The model selection index, Akaike infor-
mation criterion (AIC), of our proposed model was significantly lower than that of the 
traditional logistic regression model, indicating the superiority of our proposed model.
Group differences were identified using Pearson’s Chi squared test. Patients were 
reanalyzed after stratification according to their history of statin use, and a logistic 
regression with a random effects model was applied after adjusting for potential con-
founding. All analyses were performed using the R package and SAS statistical package 
(SAS System for Windows, version 9.1.3, SAS Institute, Cary, NC, USA). A two-tailed 
p < 0.05 indicated statistical significance.
Results
We assessed data collected from 4332 breast cancer patients and 21,660 age-matched 
controls. Comorbidities were determined using the CCI (Table 1) and by applying the 
diagnoses recorded in LHID2005. The patients with breast cancer exhibited higher rates 
of comorbid dementia (p =  0.004), chronic pulmonary disease (p =  0.009), mild liver 
disease (p < 0.001), and metastatic carcinoma (p < 0.001) than did the controls, as well 
as a significantly higher CCI score (1.63 ± 1.58 vs. 1.48 ± 1.55; p < 0.001). Significantly 
more patients with breast cancer used statins than did women in the comparison cohort 
(15.8 vs. 14.6%; p < 0.001).
Results of the analysis, stratified according to statin use (simvastatin, lovastatin, 
pravastatin, fluvastatin, or atorvastatin), are given in Table  2. The adjusted odds ratio 
(OR) for breast cancer among lovastatin users was 0.596 (95% CI 0.497–0.714), which 
was lower than that for the subjects who did not use lovastatin. Simvastatin, pravastatin, 
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Table 1 Baseline variables included demographic characteristics and  comorbid medical 
disorders for two cohorts (n = 25,992)






No % No %
Characteristics
Age (years)
 18–30 68 1.6 340 1.6
 31–40 428 9.9 2140 9.9
 41–50 1402 32.4 7010 32.4
 51–60 1306 30.1 6530 30.1
 61–70 721 16.6 3605 16.6
 >70 407 9.4 2035 9.4
Urbanization level <0.001
 Urban 1 1681 38.8 6857 31.7
 Urban 2 1273 29.4 6348 29.3
 Urban 3 566 13.1 3049 14.1
 Urban 4 455 10.5 2994 13.8
 Urban 5–7 357 8.2 2412 11.1
Comorbid medical disorders CCI
Myocardial infarction 0.206
 Yes 24 0.6 158 0.7
 No 4308 99.4 21,502 99.3
Congestive heart failure 0.179
 Yes 269 6.2 1466 6.8
 No 4063 93.8 20,194 93.2
Peripheral vascular disease 0.160
 Yes 199 4.6 1108 5.1
 No 4133 95.4 20,552 94.9
Cerebrovascular disease 0.191
 Yes 447 10.3 2385 11.0
 No 3885 89.7 19,275 89.0
Dementia 0.004
 Yes 87 2.0 601 2.8
 No 4245 98.0 21,059 97.2
Chronic pulmonary disease 0.009
 Yes 1217 28.1 5665 26.2
 No 3115 71.9 15,995 73.8
Connective tissue disease‑rheumatic disease 0.587
 Yes 323 7.5 1564 7.2
 No 4009 92.5 20,096 92.8
Peptic ulcer disease 0.057
 Yes 1470 33.9 7028 32.4
 No 2862 66.1 14,632 67.6
Mild liver disease <0.001
 Yes 1240 28.6 4849 22.6
 No 3092 71.4 16,762 77.4
Diabetes 0.065
 Yes 945 21.8 4455 20.6
 No 3387 78.2 17,205 79.4
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fluvastatin, and atorvastatin did not exhibit a statistically significant protective effect 
against breast cancer, although atorvastatin showed a protective tendency against breast 
cancer which did not reach statistical significance (adjusted OR 0.887; 95% CI 0.776–
1.013; p < 0.077).
Discussion
Our population data revealed a potential protective effect of lovastatin against breast 
cancer in Taiwanese people. Differences in breast cancer incidence between different 
ethnicities cannot be ignored. From 2004 to 2008, the incidence rates of female breast 
Table 1 continued






No % No %
Paraplegia/hemiplegia 0.420
 Yes 99 2.3 543 2.5
 No 4233 97.7 21,117 97.5
Renal disease 0.188
 Yes 180 4.2 1002 4.6
 No 4152 95.8 20,658 95.4
Moderate or severe liver disease 0.781
 Yes 14 0.3 78 0.4
 No 4318 99.7 21,582 99.6
Metastatic cancer <0.001
 Yes 339 7.8 94 0.4
 No 3993 92.2 21,566 99.6
AIDS/HIV 1.000
 Yes 0 0.0 2 0.0
 No 4332 100.0 21,658 100.0
CCI score (SD) 1.63 (1.58) 1.48 (1.55) <0.001
Medicine use
Statins 0.045
 Yes 632 14.6 3422 15.8
 No 3700 85.4 18,238 84.2
Table 2 Adjusted odds ratios (OR), and  95% confidence intervals (CIs) for  breast cancer 
in  multivariable logistic regression coupled with  a random urbanization effects model 
and stratified by statins
Variable Presence of breast cancer
Case no (%)/control no (%) Adjusted OR 95% CI p value
Statins
Atorvastatin 319(7.4)/1625(7.5) 0.887 0.776–1.013 0.077
Fluvastatin 143(3.3)/606(2.8) 1.118 0.919–1.356 0.268
Lovastatin 149(3.4)/1122(5.2) 0.596 0.497–0.714 <0.001
Pravastatin 102(2.4)/470(2.2) 1.043 0.831–1.304 0.726
Simvastatin 225(5.2)/1104(5.1) 1.037 0.886–1.215 0.647
CCI scores 1.086 1.061–1.110 <0.001
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cancer in the United States ranged from 84.9 to 125.4 cases per 100,000 women, with the 
lowest mortality from breast cancer observed in Asian Americans and Pacific Islanders 
(DeSantis et al. 2011). The association between statin use and breast cancer risk should 
therefore be evaluated in distinct ethnic populations.
In this study, we found that lovastatin produced a statistically significant protective 
effect against breast cancer after adjusting for potential confounding factors. Atorvas-
tatin exhibited only a protective tendency against breast cancer. We proposed a logistic 
regression model coupled with a random urbanization effects model to take into account 
the potential bias caused by random urbanization, and we used the CCI to evaluate 
potential comorbidities. We also adjusted for the effect of urbanization, because nutri-
tion and lifestyle are related to breast cancer incidence (Chajes and Romieu 2014).
Our study analyzed the use of five statins based on a large population database of Tai-
wanese people, and found that lovastatin showed a protective effect against breast can-
cer. In contrast to the negative findings of other current studies looking at statins and 
breast cancer risk, the large sample size of our study enhanced the results and made pos-
sible the subgroup analysis of each statin. Because of the different chemical properties of 
lipophilic and hydrophilic statins, most previous studies classified statins into these two 
groups. However, to prove an association between statin use and the risk of breast can-
cer requires each statin to be examined individually.
Several studies have suggested reasons to explain why statins are potential chemopre-
ventive agents. One study proposed that statins reduce the production of substances that 
are crucial for correct localization and translocation to cell membranes; in other words, 
statins can inhibit molecular signaling pathways (Denoyelle et al. 2001).
In 1990, lovastatin and pravastatin were introduced to the Taiwanese market as the first 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) (Li 
et al. 2010). The use of statins in Taiwan rapidly increased with the increasing need to pre-
vent coronary heart disease. Most patients who take statins are likely to be long-term users 
because of their preventive effects, the main effect being to reduce plasma cholesterol lev-
els by inhibiting a rate-limiting step in the cholesterol synthesis pathway. Statins interrupt 
the catalysis from HMG-CoA to mevalonate. The reduction of mevalonate contributes to 
a reduction of geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP). 
These compounds have an important function in molecular signaling pathways in cancer 
cells. Increasing evidence has revealed that statins have another valuable effect in prevent-
ing cancer (Boudreau et al. 2007; Jafari et al. 2013; Ahern et al. 2014). Various laboratory 
studies have demonstrated the statin-induced apoptosis of cancer cells, including breast 
cancer cells, with increasing evidence accumulating on the mechanism underlying this 
(Campbell et al. 2006; Corsini et al. 1995; Dimitroulakos et al. 2001; Niknejad et al. 2007; 
Woditschka et al. 2010; Ma et al. 2012; Niknejad et al. 2014). Preclinical findings favor the 
possibility that lovastatin exerts anticancer effects, including effects against breast cancer. 
However, despite numerous epidemiological studies, no consensus has been established 
regarding the relationship between statin use and breast cancer risk (Undela et al. 2012). 
A population-based, case–control study by Boudreau et  al. involving 1982 postmeno-
pausal women did not support an association between statin use and breast cancer risk. 
However, they suggested that long-term statin use (for longer than 5 years) was associ-
ated with a slight decrease in the risk of breast cancer (Boudreau et al. 2004). Recently, a 
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population-based case–control study using a nationwide cohort was conducted in Taiwan 
and found no evidence of an association between statin use and breast cancer (Chan et al. 
2014). That study included only patients who were aged at least 50 years, which was a nar-
rower range of age compared to our study. Furthermore, it did not analyze each statin indi-
vidually. In contrast, Pocobelli et al. reported that patients who used fluvastatin (and no 
other lipophilic statin) for less than 5 years exhibited a lower risk of breast cancer than did 
nonusers (Pocobelli et al. 2008). The Women’s Health Initiative cohort study conducted by 
Cauley et al. reported that users of lipophilic statins (e.g., lovastatin, simvastatin, and ator-
vastatin) exhibited an 18% lower breast cancer incidence than did nonusers (Cauley et al. 
2006). However, after the same cohort was followed up, it was concluded that lipophilic 
statin users exhibited no significant reductions in breast cancer risk (Desai et  al. 2013). 
Woditschka et al. investigated the association between the risk of specific breast cancer 
subtypes and lipophilic statin use, and concluded that lipophilic statin users exhibited no 
reduction in the risk of any breast cancer subtype (Woditschka et al. 2010). Kwan et al. 
reported that the risk of breast cancer recurrence in all statin users decreased with increas-
ing duration of use after diagnosis (Kwan et  al. 2008). In addition, the use of lipophilic 
statins, particularly simvastatin, was associated with significantly reduced breast cancer 
recurrence rates in a Danish nationwide cohort study (Ahern et al. 2011). In contrast, one 
case–control study observed a significantly increased risk of breast cancer in postmeno-
pausal obese women who used lipophilic statins (Eaton et al. 2009). The hypothesis that 
there is no association between statin use and breast cancer risk has been supported by 
most observational and epidemiological studies, including three meta-analyses (Undela 
et al. 2012; Bonovas et al. 2005; Dale et al. 2006). However, organ specificities for the pleo-
morphic and cholesterol-lowering effects have been observed, although the mechanism 
for this organ specificity is unknown.
Lovastatin, the first statin isolated (in 1979), has been used clinically for more than 
two decades and its lipid-lowering and other pleomorphic effects have been thoroughly 
studied (Corsini et al. 1995; Boudreau et al. 2004). Meanwhile, the effect of lovastatin on 
apoptosis has been carefully investigated (Corsini et al. 1995). One study examined 59 cell 
lines for sensitivity to lovastatin-induced apoptosis, and demonstrated that it was tumor 
specific (Dimitroulakos et al. 2001). The mechanism of lovastatin-induced apoptosis has 
been reported in several studies. Laboratory studies using mouse models of breast can-
cer demonstrated that lovastatin inhibits tumor growth and metastasis (Woditschka et al. 
2010). Niknejad et al. identified transcription factors that play a crucial role in lovastatin-
induced apoptosis in head and neck squamous cell carcinoma cell lines (Niknejad et al. 
2007), and multiple stress pathways were found to regulate the cytotoxic effects of lovas-
tatin in squamous cell carcinoma cell lines (Ma et al. 2012). Another study reported that 
certain substances enhanced lovastatin-induced apoptosis (Niknejad et al. 2014). It has 
been shown that lovastatin inhibited cell invasion and cell proliferation in breast cancer 
cell lines (Kang et al. 2009; Klawitter et al. 2010). Thus, preclinical findings support the 
possibility that lovastatin exerts anticancer effects, including effects against breast can-
cer cells. However, it should be taken into consideration that cancer cell lines in preclini-
cal studies are exposed to high concentrations of lovastatin, typically ten to one hundred 
times higher than therapeutic levels (Cho et al. 2011). Organ specificity for lovastatin’s 
cholesterol-lowering effect has been reported by several studies, and statins have been 
Page 8 of 10Murakami et al. SpringerPlus  (2016) 5:1932 
described as exhibiting organ specificity. Lovastatin inhibits cholesterol synthesis in sev-
eral organs, whereas pravastatin inhibits cholesterol synthesis mainly in the liver and 
ileum (Koga et al. 1990; Tsujita et al. 1986). This may explain why each statin exhibits dif-
ferent characteristics in terms of their pleomorphic effects.
Limitations
Some limitations of our study should be considered. First, although age, urbanization 
level, and comorbidities using the CCI were adjusted for, we did not examine other con-
founding factors that may have influenced results of this study, such as age at menarche, 
age at menopause, a family history of breast cancer, a history of benign breast disease, 
postmenopausal hormone replacement use, and the mammographic screening status 
(Eliassen et al. 2005). Second, it is impossible to ensure that all patients who were pre-
scribed statins complied with their treatments. In addition, data about doses and dura-
tion were not available. Third, each statin has been available in the Taiwanese market 
for different periods of time, and these differences may have influenced the statisti-
cal results. Fourth, because of the limitation of the time range of the database, which 
included only the seven years between 2004 and 2010, our study included participants 
exposed to statins within the 3 years prior to the index date when their breast cancer was 
diagnosed. However, 3 years may be not long enough to develop or prevent a cancer, and 
statin users are expected to take the medication lifelong to treat hyperlipidemia. Further 
study over a longer exposure time may be needed in the future.
Conclusions
In summary, although no consensus has been established regarding the relationship 
between statin use and breast cancer risk, our study indicated that lovastatin is a poten-
tial chemopreventive agent against breast cancer. Further detailed research is warranted.
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